News Alfresa Holdings Corporation

Stocks

2784

JP3126340003

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange 02:30:00 2026-10-29 EDT			5-day change	1st Jan Change
2,440.00 ^JPY	+1.04%		+2.87%	+0.37%

10-05	Healios Completes First 144 Million Yen Culture Supernatant Shipment to JENECEL	MT
06-30	Ember LifeSciences, Inc. announced that it has received funding from Alfresa Holdings Corporation	CI

All News

Mentions Relevance

10-05	Healios Completes First 144 Million Yen Culture Supernatant Shipment to JENECEL	MT
07-30	Ember LifeSciences and Alfresa Corporation Enter into Capital and Business Alliance to Improve the Quality of the Pharmaceutical Cold Chain in Japan	AQ
06-30	Ember LifeSciences, Inc. announced that it has received funding from Alfresa Holdings Corporation	CI
06-21	Alfresa Holdings Corporation(TSE:2784) dropped from S&P Japan Mid Cap 100	CI
05-26	ReeNT Co., Ltd. announced that it expects to receive ¥600 million in funding from Alfresa Holdings Corporation	CI
05-26	Alfresa Holdings Corporation concluded a share transfer agreement to acquire Nagashima Medical Instruments Co., Ltd. from Nagashima Holdings Co., Ltd.	CI
05-19	Alfresa : Acquisition of ISMS Certification by GEKKA WORKS Co., Ltd. for Managing Provision of its Communication Service for Healthcare and Caregiving Professionals	PU
05-18	Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2026, has closed with 6,307,800 shares, representing 3.47% for ¥14,999.95 million.	CI
05-18	Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2026.	CI
05-17	Alfresa : Notice on the Decision of Terms of the 1st Issuance of Stock Acquisition Right via Third-Party Allotment for Acquisition of Own Shares via Fully Committed Share Repurchase (Japanese ASR)	PU
05-17	Alfresa : Notice of the Result and Completion of the Acquisition of Own Shares through Off-Auction Own Share Repurchase Trading System(ToSTNeT-3)	PU
05-15	Alfresa Holdings Corporation authorizes a Buyback Plan.	CI
05-15	Alfresa Holdings Corporation announces an Equity Buyback for 6,307,800 shares, representing 3.46% for ¥14,999.95 million.	CI
05-15	Alfresa : Briefing on Business Results for the Fiscal Year Ended March 2026 （2,633KB） PDF	PU
05-15	Alfresa Holdings Corp - to buy back up to 3.5% of own shares worth about 15 billion yen	RE
05-15	Alfresa : Notice Regarding Partial Amendments to the Articles of Incorporation	PU
05-15	Alfresa : Consolidated Financial Results for the Fiscal Year Ended March 31, 2026(Under Japanese GAAP)	PU
05-15	Alfresa : Financial Results Summary for the Fiscal Year Ended March 31, 2026	PU
05-15	Alfresa Holdings Corporation Announces Cash Dividend for the Year-End of the Fiscal Year Ended March 31, 2026, Payable on June 2, 2026; Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of the Fiscal Year Ending March 31, 2027	CI
05-15	Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Fiscal Year Ending March 31, 2027	CI
05-14	Alfresa : Notice Regarding the Establishment of a Collaborative Research Laboratory in Clinical and Emerging Infectious Diseases at Hiroshima University Hospital Aimed at Strengthening Countermeasures for a Tick-Borne Infectious Disease Deepening Collaboration Between Industry and Academia to Advance Research and Education, Promote Implementation in Industry, and Contribute to Society	PU
04-28	Alfresa : Notice Regarding the Business Alliance Between Alfresa Healthcare Corporation and AdInte Co., Ltd. to Jointly Develop a Retail Media Business to Support the Sales Promotion Activities of Manufacturers and Retailers	PU
04-28	Alfresa : Conclusion of a Comprehensive Partnership Agreement Between Meisho Co., Ltd. and Komatsu City, Ishikawa Prefecture, to Promote the Health of and Realize Safe and Comfortable Lives for the City’s Residents	PU
04-07	Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material	MT
03-31	Alfresa : Notice Regarding the Business Alliance Between Mwis Corporation and Ark Medical Solutions Inc. to Expand the Latter’s CRO Business	PU